Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
FAIL · Does not pass the screen
1.74 USD
At the last full screen 2025-12-31
Screened 2025-12-31 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Nautilus Biotechnology Inc holds its Markup at $1.74. The statistical read favours the sellers, held for 27 days.
As held on the ledger · 2025-12-31
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 27 days
Price at the screen
$1.74
Valuation
N/A trailing · -2.35 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.81
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
15.71%
Below 33%
Interest-bearing debt is just 15.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
47.63%
Below 33%
Interest-bearing cash and securities are 47.6% of assets, above the one-third limit.
Fail
Receivables
6.48%
Below 49%
Money owed to the company is 6.5% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2025-12-31 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2025-12-31 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NAUT trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-06Accumulation · changed$1.74+0.0%Entry 5
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 33% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 205%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (1 analysts) rates it none, with a mean price target of $4.
2026-08-06Distribution$1.74-22.3%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 22.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 33% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 205%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (1 analysts) rates it none, with a mean price target of $4.
2026-07-18Distribution$2.24+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 33% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 205%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (1 analysts) rates it none, with a mean price target of $4.
2026-07-03Distribution$2.24+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$2.24Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.